Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205320 | 1.00 | MDM2 (0.50) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL31437132 | 1.00 | MDM2 (0.50) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL3205240 | 1.00 | MDM2 (0.50) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL3205062 | 0.96 | ACE (0.52) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL20946311 | 0.96 | ACE (0.52) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL3204577 | 0.96 | ACE (0.52) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL23042775 | 0.92 | ACE (0.49) | MDM2MDM4TP53ACECTSS | |
| SCHEMBL30441027 | 0.92 | ACE (0.49) | MDM2MDM4TP53ACECTSS | |
| SCHEMBL30441164 | 0.92 | ACE (0.49) | MDM2MDM4TP53ACECTSS | |
| SCHEMBL23042774 | 0.92 | ACE (0.49) | MDM2MDM4TP53ACECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810129-B1 | PCSK9 ANTAGONIST BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3504197-B1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-07-15 | — | — | US | disclosed |
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3810129-A1 | PCSK9 ANTAGONIST BICYCLO-COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3423467-B1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-28 | — | — | EP | disclosed |
| US-10870623-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3504197-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-07-03 | — | — | EP | disclosed |
| EP-3423469-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-01-09 | — | — | EP | disclosed |
| US-20180371016-A1 | TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180371015-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2018036957-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-01 | — | — | WO | disclosed |
| US-20090005419-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | PCSK9, PCSK7, PCSK6 | MDM2 4586/4885MDM4 4847/4885TP53 4061/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MDM2 3730/4885MDM4 934/4885TP53 3426/4885 |
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HTRA1, HTR1A, HTR1E | MDM2 2636/4885MDM4 3913/4885TP53 2411/4885 |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | MDM2 4586/4885MDM4 4847/4885TP53 4061/4885 |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HTRA1, HTR3E, HTR1F | MDM2 3600/4885MDM4 4588/4885TP53 3334/4885 |
| US-20090005419-A1 | Organic Compounds | ELAVL1, RBM3, RRBP1 | MDM2 639/4885MDM4 982/4885TP53 503/4885 |
| US-20180371016-A1 | TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HTRA1, HTR3E, HTR1F | MDM2 3600/4885MDM4 4588/4885TP53 3334/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | MDM2 2451/4885MDM4 963/4885TP53 81/4885 |
| US-10870623-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HTRA1, HTR1A, HTR1F | MDM2 3998/4885MDM4 4638/4885TP53 3731/4885 |
| US-20180371015-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HTRA1, HTR1A, HTR1E | MDM2 3309/4885MDM4 4132/4885TP53 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.